We are live on ! Find out more
BCTXL icon

BriaCell Therapeutics Warrant expiring 2031

15 hedge funds and large institutions have $3.7M invested in BriaCell Therapeutics Warrant expiring 2031 in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

127.95% more ownership

Funds ownership: 0% → 127.95% (+128%)

Holders
15
Holders Change
+15
Holders Change %
–
% of All Funds
0.18%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
15
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BCTXL Hedge Fund Activity: Q1 2026 in Review

15 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Warrant expiring 2031 (BCTXL) for Q1 2026, worth a combined $3.7M.

Buyers outnumbered sellers: 15 funds opened new BCTXL positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $1.11M.

  • 15 institutional investors held BriaCell Therapeutics Warrant expiring 2031 (BCTXL) as of Q1 2026, up from 0 in Q4 2025.
  • Funds reported $3.7M of BriaCell Therapeutics Warrant expiring 2031 stock for Q1 2026.
  • 15 funds opened new BriaCell Therapeutics Warrant expiring 2031 positions in Q1 2026 and 0 closed out, a net change of +15 holders.
  • The largest BriaCell Therapeutics Warrant expiring 2031 buyer in Q1 2026 was Citadel Advisors, an estimated $1.11M added.

Based on aggregated 13F filings for Q1 2026.